Literature DB >> 10937769

The immune response to chronic Pseudomonas aeruginosa lung infection in cystic fibrosis patients is predominantly of the Th2 type.

C Moser1, S Kjaergaard, T Pressler, A Kharazmi, C Koch, N Høiby.   

Abstract

Most cystic fibrosis (CF) patients with chronic Pseudomonas aeruginosa lung infection have a persistent acute type lung inflammation dominated by polymorphonuclear neutrophils (PMN) and a pronounced antibody response against P. aeruginosa. We speculated whether this immune response in CF is of the Th2 type and whether a change to a Th1 type immune response could improve the prognosis. Therefore, we studied 14 CF patients with (CF +P) and 14 CF patients without (CF -P) chronic P. aeruginosa lung infection. The specific production of interferon-gamma (IFN-gamma) and interleukin-4 (IL-4) by peripheral blood mononuclear cells was determined. Cells from CF +P patients had lower IFN-gamma (p<0.05) and higher IL-4 (p<0.005) production as compared to cells from CF -P patients. Furthermore, a positive correlation between IFN-gamma production and lung function was found (FVC: Rho = 0.637; p<0.03; FEV1: Rho=0.524; p<0.07). We conclude that a Th2 type immune response is most frequent in CF patients with chronic P. aeruginosa lung infection, and the patients with a Th1-dominated immune response had the best lung function. The clinical implication is that a change to a Th1 type immune response might improve the prognosis in these patients.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10937769     DOI: 10.1034/j.1600-0463.2000.d01-64.x

Source DB:  PubMed          Journal:  APMIS        ISSN: 0903-4641            Impact factor:   3.205


  59 in total

Review 1.  Asthma in cystic fibrosis.

Authors:  Ian M Balfour-Lynn
Journal:  J R Soc Med       Date:  2003       Impact factor: 5.344

Review 2.  "CF asthma": what is it and what do we do about it?

Authors:  I M Balfour-Lynn; J S Elborn
Journal:  Thorax       Date:  2002-08       Impact factor: 9.139

3.  Biofilms 2003: emerging themes and challenges in studies of surface-associated microbial life.

Authors:  Matthew R Parsek; Clay Fuqua
Journal:  J Bacteriol       Date:  2004-07       Impact factor: 3.490

4.  Lymphocytes in cystic fibrosis lung disease: a tale of two immunities.

Authors:  R B Moss
Journal:  Clin Exp Immunol       Date:  2004-03       Impact factor: 4.330

5.  The role of CFTR mutations in asthma.

Authors:  Andrew Sandford
Journal:  Can Respir J       Date:  2012 Jan-Feb       Impact factor: 2.409

6.  Immunological considerations in the development of Pseudomonas aeruginosa vaccines.

Authors:  Sarah M Baker; James B McLachlan; Lisa A Morici
Journal:  Hum Vaccin Immunother       Date:  2019-09-05       Impact factor: 3.452

7.  Cellular immunity in healthy volunteers treated with an octavalent conjugate Pseudomonas aeruginosa vaccine.

Authors:  A W Zuercher; M A Imboden; S Jampen; D Bosse; M Ulrich; H Chtioui; B H Lauterburg; A B Lang
Journal:  Clin Exp Immunol       Date:  2006-01       Impact factor: 4.330

Review 8.  Monitoring inflammation in CF. Cytokines.

Authors:  Scott D Sagel; Frank J Accurso
Journal:  Clin Rev Allergy Immunol       Date:  2002-08       Impact factor: 8.667

Review 9.  Pseudomonas aeruginosa biofilms in disease.

Authors:  Lawrence R Mulcahy; Vincent M Isabella; Kim Lewis
Journal:  Microb Ecol       Date:  2013-10-06       Impact factor: 4.552

10.  Faster activation of polymorphonuclear neutrophils in resistant mice during early innate response to Pseudomonas aeruginosa lung infection.

Authors:  P Ø Jensen; C Moser; O Kobayashi; H P Hougen; A Kharazmi; N Høiby
Journal:  Clin Exp Immunol       Date:  2004-09       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.